Literature DB >> 279711

Relation between component parts of fibrocystic disease complex and breast cancer.

D L Page, R Vander Zwaag, L W Rogers, L T Williams, W E Walker, W H Hartmann.   

Abstract

Specimens of benign breast disease obtained from biopsies performed at Vanderbilt Hospital (Nashville, Tenn.) between 1952 and 1959 were histologically reviewed and characterized as to individual component types of fibrocystic disease. Follow-up for information regarding breast cancer development was 94% successful. Carcinoma developed more often when epithelial proliferative lesions were present. Atypical lobular hyperplasia had a greater predictive value than other epithelial lesions and was associated with an elevated risk six times that expected prior to the age of 45 years and a tripling of risk after the age of 45 years. Various ductal hyperplastic lesions are associated with approximately a doubly increased risk that is present only if the lesions are identified at biopsy after the age of 45 years. Women with cysts, sclerosing adenosis, fibrosis, and other nonhyperplastic changes were at no greater risk for subsequent carcinoma than women in the general population.

Entities:  

Mesh:

Year:  1978        PMID: 279711

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  43 in total

Review 1.  The basic pathology of human breast cancer.

Authors:  E Mallon; P Osin; N Nasiri; I Blain; B Howard; B Gusterson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-04       Impact factor: 2.673

2.  An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part I: Normal breast and benign proliferative lesions.

Authors:  W Böcker; B Bier; G Freytag; B Brömmelkamp; E D Jarasch; G Edel; B Dockhorn-Dworniczak; K W Schmid
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 3.  Biochemical study of cyst fluid in human breast cystic disease: a review.

Authors:  C L Enriori; J E Novelli; M del C Cremona; R J Hirsig; P J Enriori
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Detection of estradiol-induced messenger RNA (pS2) in uninvolved breast tissue from mastectomies for breast cancer.

Authors:  E Hähnel; R Joyce; G Sterrett; J Harvey; R Hähnel
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

5.  Surgical biopsy findings in patients with atypical hyperplasia diagnosed by stereotaxic core needle biopsy.

Authors:  I Tocino; B M Garcia; D Carter
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

6.  Cigarette smoking and benign proliferative epithelial disorders of the breast in women: a case-control study.

Authors:  T E Rohan; M G Cook; J A Baron
Journal:  J Epidemiol Community Health       Date:  1989-12       Impact factor: 3.710

7.  C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast.

Authors:  Filiz Eren; Zerrin Calay; Haydar Durak; Bülent Eren; Nil Comunoğlu; Ovgü Aydin
Journal:  Bosn J Basic Med Sci       Date:  2012-02       Impact factor: 3.363

Review 8.  Anatomic indicators (histologic and cytologic) of increased breast cancer risk.

Authors:  D L Page; W D Dupont
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

9.  Cellular proliferative activity of mammographic normal dense and fatty tissue determined by DNA S phase percentage.

Authors:  P C Stomper; R B Penetrante; S B Edge; M A Arredondo; L E Blumenson; C C Stewart
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

10.  An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part II: Epitheliosis and ductal carcinoma in situ.

Authors:  W Böcker; B Bier; G Freytag; B Brömmelkamp; E D Jarasch; G Edel; B Dockhorn-Dworniczak; K W Schmid
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.